Shares shifted as Aehr Test Systems extended a furious post-earnings rally, trading at $82.91 (+7.2%) after last week's fiscal Q4 report ignited buying that initially sent the stock up 30% in a single session. The question now: whether a small semiconductor-equipment maker can execute one of the most aggressive growth promises in the chip sector.
A Guidance Bomb That Blindsided Wall Street
Aehr projected fiscal 2027 revenue of $130 million–$150 million, implying 160%–200% year-over-year growth — and substantially surpassing the analyst consensus estimate of just $85 million.
Full-year fiscal 2026 revenue was only $50 million, down from $59 million the prior year , meaning management is asking investors to believe the company will nearly triple sales in twelve months. This outlook is underpinned by a roughly $100 million effective backlog and targeted profit margins (before taxes) of 18%–22% of revenue.
AI Replaced Electric Vehicles as the Growth Engine
Management described fiscal 2026 as a transition year, shifting its primary revenue base from electric-vehicle silicon carbide applications to AI and data-center infrastructure.
AI processors and silicon photonics testing — essentially stress-testing chips used in AI servers and high-speed optical links — accounted for over 80% of Q4 revenue, up from 56% a year ago.
Roughly 95% of fiscal 2026 revenue came from non-EV applications. That pivot matters because AI infrastructure spending is accelerating while EV chip demand has been uneven.
Record Bookings Show Real Orders, Not Just Forecasts
Quarterly bookings surged more than 500% year over year to $60.7 million from $11.1 million.
Non-GAAP earnings of $0.11 per share crushed the consensus estimate by 1,200% , and gross margins expanded to 45% from 35%, reflecting better factory utilization and a more favorable product mix.
Valuation Is Rich, and Execution Risk Is Real
At the midpoint of guidance, the stock trades at roughly 20 times forward sales — high by most standards, though down about 56% from its peak valuation.
Analysts at Craig Hallum and Lake Street Capital set price targets of $125 and $110, implying roughly 40% upside from current levels.
Yet the company still carries negative net income and negative free cash flow , and moderate short interest and recent insider selling highlight positioning risk. Converting a $100 million backlog into shipped revenue — without stumbling on manufacturing scale-up — is the single biggest test ahead.